Advertisement
Advertisement
U.S. Markets open in 3 hrs 35 mins
Advertisement
Advertisement
Advertisement
Advertisement

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
147.50+1.20 (+0.82%)
At close: 04:00PM EDT
147.95 +0.45 (+0.31%)
After hours: 07:05PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close146.30
Open147.68
Bid0.00 x 1000
Ask0.00 x 1100
Day's Range144.38 - 148.25
52 Week Range117.58 - 212.00
Volume1,629,326
Avg. Volume892,846
Market Cap17.641B
Beta (5Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)-7.13
Earnings DateApr 27, 2022 - May 02, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est208.20
  • Investopedia

    A Look Into Foreign Direct Investment Trends

    Foreign direct investments play an important role as an indicator of a healthy economy in terms of economic growth and long-term capital movement.

  • American City Business Journals

    The Petri Dish: Amylyx, Alnylam net drug approvals

    The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings. Canada approves Amylyx drug Amylyx Pharmaceuticals Inc. (Nasdaq: AMLX) scored its first-ever approval from Health Canada for its amyotrophic lateral sclerosis (ALS) drug Albrioza.

  • Zacks

    Alnylam's (ALNY) Rare Disease Drug, Amvuttra, Gets FDA Nod

    The FDA approves Alnylam's (ALNY) Amvuttra (vutrisiran) to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

Advertisement
Advertisement